The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cells

This publication has 29 references indexed in Scilit:

• A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways
  International Immunology, 2002
• Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
  Nature Immunology, 2002
• Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
  Nature Immunology, 2002
• Reversal of human allergen-specific CRTH2+ TH2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide
  Journal of Allergy and Clinical Immunology, 2001
• Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study
  The Journal of Infectious Diseases, 2001
• The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' Cells
  Clinical Immunology, 2000
• Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S‐28463: Efficacy and Mode of Action
  The Journal of Infectious Diseases, 1999
• Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod
  Cellular Immunology, 1999
• Polyinosinic acid: polycytidylic acid promotes T helper type 1‐specific immune responses by stimulating macrophage production of interferon‐α and interleukin‐12
  European Journal of Immunology, 1995
• Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones.
  The Journal of Experimental Medicine, 1994